3-hydroxykynurenine has been researched along with Depressive Disorder, Major in 7 studies
3-hydroxykynurenine: RN given refers to cpd without isomeric designation
3-hydroxykynurenine : A hydroxykynurenine that is kynurenine substituted by a hydroxy group at position 3.
hydroxykynurenine : A hydroxy-amino acid that is kynurenine substituted by a single hydroxy group at unspecified position. A "closed" class.
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Depression is hypothesized to be causally associated with an imbalance in the kynurenine pathway, with an increased metabolism down the 3-hydroxykynurenine (3HK) branch of the pathway leading to increased levels of the neurotoxic metabolite, quinolinic acid (QA), which is a putative N-methyl-d-aspartate (NMDA) receptor agonist." | 3.85 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| "A subgroup of individuals with mood and psychotic disorders shows evidence of inflammation that leads to activation of the kynurenine pathway and the increased production of neuroactive kynurenine metabolites." | 3.85 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| " In contrast, schizophrenia and psychosis are hypothesized to arise from increased metabolism of the NMDA receptor antagonist, kynurenic acid (KynA), leading to hypofunction of GABAergic interneurons, the disinhibition of pyramidal neurons and striatal hyperdopaminergia." | 3.85 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| "Depression is hypothesized to be causally associated with an imbalance in the kynurenine pathway, with an increased metabolism down the 3-hydroxykynurenine (3HK) branch of the pathway leading to increased levels of the neurotoxic metabolite, quinolinic acid (QA), which is a putative N-methyl-d-aspartate (NMDA) receptor agonist." | 1.46 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wurfel, BE | 3 |
| Drevets, WC | 4 |
| Bliss, SA | 1 |
| McMillin, JR | 1 |
| Suzuki, H | 1 |
| Ford, BN | 2 |
| Morris, HM | 2 |
| Teague, TK | 4 |
| Dantzer, R | 4 |
| Savitz, JB | 1 |
| Savitz, J | 3 |
| Smith, CM | 1 |
| Victor, TA | 2 |
| Bellgowan, PS | 1 |
| Bodurka, J | 3 |
| Meier, TB | 1 |
| Young, KD | 1 |
| Tashiro, T | 1 |
| Murakami, Y | 1 |
| Mouri, A | 1 |
| Imamura, Y | 1 |
| Nabeshima, T | 1 |
| Yamamoto, Y | 1 |
| Saito, K | 1 |
| Van Gool, AR | 1 |
| Verkerk, R | 1 |
| Fekkes, D | 1 |
| Bannink, M | 1 |
| Sleijfer, S | 1 |
| Kruit, WH | 1 |
| van der Holt, B | 1 |
| Scharpé, S | 1 |
| Eggermont, AM | 1 |
| Stoter, G | 1 |
| Hengeveld, MW | 1 |
| Laugeray, A | 1 |
| Launay, JM | 1 |
| Callebert, J | 1 |
| Surget, A | 1 |
| Belzung, C | 1 |
| Barone, PR | 1 |
7 other studies available for 3-hydroxykynurenine and Depressive Disorder, Major
| Article | Year |
|---|---|
Serum kynurenic acid is reduced in affective psychosis.
Topics: Adult; Affective Disorders, Psychotic; Bipolar Disorder; Corpus Striatum; Cytokines; Depression; Dep | 2017 |
Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder.
Topics: Adult; Amygdala; Anhedonia; Brain-Derived Neurotrophic Factor; C-Reactive Protein; Depressive Disord | 2015 |
Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder.
Topics: Adult; Brain; C-Reactive Protein; Case-Control Studies; Cerebral Cortex; Depressive Disorder, Major; | 2016 |
Kynurenine pathway metabolites are associated with hippocampal activity during autobiographical memory recall in patients with depression.
Topics: Adult; Depressive Disorder, Major; Female; Hippocampus; Humans; Kynurenic Acid; Kynurenine; Magnetic | 2016 |
Kynurenine 3-monooxygenase is implicated in antidepressants-responsive depressive-like behaviors and monoaminergic dysfunctions.
Topics: Animals; Antidepressive Agents; Biogenic Monoamines; Depressive Disorder, Major; Disease Models, Ani | 2017 |
Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon-alpha: course and relationship with psychiatric status.
Topics: Adult; Aged; Brain; Carcinoma, Renal Cell; Depressive Disorder, Major; Dose-Response Relationship, D | 2008 |
Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression.
Topics: Animals; Brain; Chronic Disease; Depressive Disorder, Major; Disease Models, Animal; Hydroxyindoleac | 2010 |